Medical Letter on the CDC & FDA
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC & FDA
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Allergy Medicine
Bifidobacterium bifidum G9-1 suppresses IgE production
October 23rd, 2005
Oral administration of Bifidobacterium bifidum G9-1 suppresses total and antigen-specific immunoglobulin E production in mice. According to recent research published in the journal Biological and Pharmaceutical Bulletin, "Recent studies have suggested that oral bacteriotherapy with probiotics might be useful in the management of allergic diseases. We investigated the effect of oral administration of Bifidobacterium bifidum G9-1 (BBG9-1) on immunoglobulin (Ig) E production in BALB/c mice. Live BBG9-1 was orally administered to mice for 2 weeks from 1 week before ovalbumin (OVA)-immunization." "The treatment of BBG9-1 significantly...
Source: Medical Letter on the CDC & FDA (2005-10-23)
|
